UCB‘s Cimzia has received approval from the FDA for the treatment of adult patients with active psoriatic arthritis (PsA). A Phase III study showed that Cimzia rapidly improved the signs and symptoms of PsA for patients with response observed as early as the first week of treatment for some patients. In the U.S., Cimzia is also approved for the treatment of adults with moderately to severely active rheumatoid arthritis. In addition, it is approved for reducing signs and symptoms of Crohn&...